Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment
MT Newswires Live
Yesterday
Natera (NTRA) said Wednesday that patient enrollment has begun for a trial using its Signatera test to identify patients who may need earlier intervention by detecting persistent molecular residual disease before radiographic progression.
The company said the study will use Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, which is an aggressive type of skin cancer. It said the current standard of care is a combination immunotherapy until clinical progression.
The company said the primary endpoint is progression-free survival.
The study is sponsored by NYU Langone Health.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.